SEARCH

SEARCH BY CITATION

References

  • 1
    The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New England Journal of Medicine 2000; 342: 13018.
  • 2
    The ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. Journal of the American Medical Association 2012; 307: 252633.
  • 3
    dos Santos CC, Slutsky AS. The contribution of biophysical lung injury to the development of biotrauma. Annual Review of Physiology 2006; 68: 585618.
  • 4
    Uhlig S, Uhlig U. Pharmacological interventions in ventilator-induced lung injury. Trends in Pharmacological Sciences 2004; 25: 592600.
  • 5
    Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. American Journal of Respiratory Cell and Molecular Biology 2011; 44: 72538.
  • 6
    Patel BV, Wilson MR, Takata M. Resolution of acute lung injury and inflammation: a translational mouse model. European Respiratory Journal 2012; 39: 116270.
  • 7
    Reiss LK, Uhlig U, Uhlig S. Models and mechanisms of acute lung injury caused by direct insults. European Journal of Cell Biology 2012; 91: 590601.
  • 8
    Zosky GR, Janosi TZ, Adamicza A, et al. The bimodal quasi-static and dynamic elastance of the murine lung. Journal of Applied Physiology 2008; 105: 68592.
  • 9
    dos Santos CC, Shan Y, Akram A, et al. Neuroimmune regulation of ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine 2011; 183: 47182.
  • 10
    Vaporidi K, Francis RC, Bloch KD, et al. Nitric oxide synthase 3 contributes to ventilator-induced lung injury. American Journal of Physiology-Lung Cellular and Molecular Physiology 2010; 299: L1509.
  • 11
    Wilson MR, O'Dea KP, Zhang D, et al. Role of lung-marginated monocytes in an in vivo mouse model of ventilator-induced lung injury. American Journal of Respiratory and Critical Care Medicine 2009; 179: 91422.
  • 12
    Wilson MR, Patel BV, Takata M. Ventilation with “clinically relevant” high tidal volumes does not promote stretch-induced injury in the lungs of healthy mice. Critical Care Medicine 2012; 40: 28507.
  • 13
    Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. Journal of the American Medical Association 2010; 303: 86573.
  • 14
    Putensen C, Theuerkauf N, Zinserling J, et al. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Annals of Internal Medicine 2009; 151: 56676.
  • 15
    Wilson MR, Choudhury S, Goddard ME, et al. High tidal volume upregulates intrapulmonary cytokines in an in vivo mouse model of ventilator-induced lung injury. Journal of Applied Physiology 2003; 95: 138593.
  • 16
    Yang G, Hamacher J, Gorshkov B, et al. The dual role of TNF in pulmonary edema. Journal of Cardiovascular Disease Research 2010; 1: 2936.
  • 17
    Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respiratory Research 2006; 7: 125.
  • 18
    Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet 1998; 351: 92933.
  • 19
    Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Critical Care Medicine 2001; 29: 50310.
  • 20
    Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. Journal of the American Medical Association 1995; 273: 93441.
  • 21
    Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine 1996; 24: 143140.
  • 22
    Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. New England Journal of Medicine 1996; 334: 1697702.
  • 23
    Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 2004; 32: 217382.
  • 24
    Al-Lamki RS, Brookes AP, Wang J, et al. TNF receptors differentially signal and are differentially expressed and regulated in the human heart. American Journal of Transplantation 2009; 9: 267996.
  • 25
    Wilson MR, Goddard ME, O'Dea KP, et al. Differential roles of p55 and p75 tumor necrosis factor receptors on stretch-induced pulmonary edema in mice. American Journal of Physiology-Lung Cellular and Molecular Physiology 2007; 293: L608.
  • 26
    Bertok S, Wilson MR, Dorr AD, et al. Characterization of TNF receptor subtype expression and signaling on pulmonary endothelial cells in mice. American Journal of Physiology-Lung Cellular and Molecular Physiology 2011; 300: L7819.
  • 27
    Dorr AD, Wilson MR, Wakabayashi K, et al. Sources of alveolar soluble TNF receptors during acute lung injury of different etiologies. Journal of Applied Physiology 2011; 111: 17784.
  • 28
    Bertok S, Wilson MR, Morley PJ, et al. Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury. Thorax 2012; 67: 24451.